Cannabis and Hemp Research Firm Oasis Intelligence Named Hilary Craven, Dr. Stuart Silverman to Board
The Dank Investor Posted On January 29, 2020 
Oasis Intelligence announced official appointments to its Board of Advisors, Founder of Sidecar, Hilary Craven and Stuart Silverman, M.D. The Oasis Cannabis and Hemp Industry Tracker™ is the largest proprietary study of consumer attitudes, perceptions and usage in the cannabis and hemp industry driven by a 20,000-person, state-by-state national survey. Now Oasis benefits from two experts from the brand marketing and medical cannabis fields.
“These two experts put Oasis at an immediate advantage. We can better understand the patient journey through Dr. Silverman’s experience and with Hilary Craven on our side we can better serve brands in need of leveraging data for successful growth.”
With nearly 20 years’ experience, Hilary Craven is Founder and Chief Marketing Officer of the marketing company Sidecar, coming from high profile advertising shops including 72andSunny. There she developed and implemented brand and communication strategies for blue chip companies including Sonos, Tillamook, Activision, Samsung, Nike, and Target. Since launching Sidecar, the company has consulted for influential, innovative cannabis brands including dosist.
Her entrepreneurial and leadership experience has allowed her to now act as an advisor for c-level executives and venture capitalists looking for support in brand identity, articulation and global communication strategy. She is energized around applying her knowledge to this evolving category and continuing to create work that resonates in culture in relevant ways.
Stuart Silverman, M.D. is a rheumatology physician, cannabis clinician and researcher in private practice. He is a clinical Professor at Cedars Sinai Medical Center and the David Geffen School of Medicine at UCLA, and a faculty member of the UCLA Cannabis Research Initiative. He’s spoken widely on cannabis nationally from Princeton University to locally at TEC-Leimert and giving Grand Rounds on cannabis at Cedars Sinai and UCLA.
He served on the Scientific Advisory Board of Kalytera Pharma, which is developing CBD and cannabinoids for treatment of disease, and worked with Niamedic, an Israeli healthcare and research company specialized in integrating medical cannabis treatments. Author of 200+ peer reviewed papers, graduate of Princeton University and Johns Hopkins medical school, he completed medical training in internal medicine at Boston University.
